Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (60)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Fekety, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Fekety, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 753-758
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

Glenn W. Kaatza,*, Steven L. Barriereb, Dennis R. Schaberga and Robert Feketya

aDepartment of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical Center Ann Arbor, MI 48109, U.S.A. bDepartments of Pharmaceutical Services and Internal Medicine, Division of Infectious Diseases, University of California Los Angeles, CA 90024, U.S.A.

accepted 24 June 1987

The efficacy of ciprofloxacin was compared with that of vancomycin in the rabbit model of methicillin-susceptible Staphylococcus aureus endocarditis. Animals were treated with ciprofloxacin, 25 mg/kg iv every 8 h or vancomycin, 17.5 mg/kg iv every 6 h, for 3, 6, or 9 days. Both drugs were found to be equally effective in the therapy of this infection, but the degree of reduction in bacterial counts was less than expected on the basis of previous studies. Additionally, resistance to ciprofloxacin in the test strain of S. aureus was seen to emerge in 12.5% of animals that received the drug. This raises concern about the use of ciprofloxacin as a single agent in the therapy of humans with serious systemic S. aureus infections.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
E. C. J. Smith, G. W. Kaatz, S. M. Seo, N. Wareham, E. M. Williamson, and S. Gibbons
The Phenolic Diterpene Totarol Inhibits Multidrug Efflux Pump Activity in Staphylococcus aureus
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4480 - 4483.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. T. Tsuji and M. J. Rybak
Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2735 - 2745.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. W. Kaatz, R. V. Thyagarajan, and S. M. Seo
Effect of Promoter Region Mutations and mgrA Overexpression on Transcription of norA, Which Encodes a Staphylococcus aureus Multidrug Efflux Transporter
Antimicrob. Agents Chemother., January 1, 2005; 49(1): 161 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. W. Kaatz, V. V. Moudgal, S. M. Seo, and J. E. Kristiansen
Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus
Antimicrob. Agents Chemother., February 1, 2003; 47(2): 719 - 726.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. M. Entenza, J. Vouillamoz, M. P. Glauser, and P. Moreillon
Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis
Antimicrob. Agents Chemother., January 1, 1999; 43(1): 77 - 84.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
G. W. Kaatz, S. M. Seo, J. R. Aeschlimann, H. H. Houlihan, R.-C. Mercier, and M. J. Rybak
Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis
Antimicrob. Agents Chemother., February 1, 1998; 42(2): 254 - 256.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.